拨康视云-B2025中期报告

(Incorporated in the Cayman Islands with limited liability)（於開曼群島註冊成立的有限公司） Stock Code股份代號: 2592 INTERIM REPORT2025中期報告 Contents 1.Corporate Information22.Condensed Consolidated Interim Statement of Comprehensive Income53.Condensed Consolidated Interim Statement of Financial Position64.Condensed Consolidated Interim Statement of Changes in Equity75.Condensed Consolidated Interim Statement of Cash Flows96.Notes to the Condensed Consolidated Interim Financial Information107.Management Discussion and Analysis338.Corporate Governance and Other information619.Glossary86 Corporate Information BOARD OF DIRECTORS Executive Directors Ni JinsongDinh Son VanYang Rong Ni JinsongDinh Son VanYang Rong Non-executive Directors Li Jun ZhiCao XuXia Zhidong Li Jun Zhi Independent Non-executive Directors 202531420253142025314 Lai Hin Wing Henry Stephen(appointed on 14 March 2025)Liu Chung Mun(appointed on 14 March 2025)Nie Sijiang(appointed on 14 March 2025) COMMITTEES Audit Committee Liu Chung Mun(Chairman)Nie SijiangLai Hin Wing Henry Stephen Remuneration Committee Nie Sijiang(Chairlady)Lai Hin Wing Henry StephenLiu Chung Mun Nomination Committee Lai Hin Wing Henry Stephen(Chairman)Nie SijiangLiu Chung Mun Company Secretary 20255122025625 Fung Nga Fong(appointed on 12 May 2025)Au Thomas Tsz Ngai(resigned on 25 June 2025) Authorised Representatives Ni JinsongFung Nga Fong Ni Jinsong REGISTERED OFFICE: 4th Floor, Harbour Place103 South Church StreetP.O. Box 10240Grand Cayman KY1-1002Cayman Islands 4th Floor, Harbour Place103 South Church StreetP.O. Box 10240Grand Cayman KY1-1002Cayman Islands PRINCIPAL PLACE OF BUSINESS AND HEAD OFFICE INTHE U.S. 8921 Research DriveIrvine, CA 92618United States 8921 Research DriveIrvine, CA 92618United States PRINCIPAL PLACE OF BUSINESS IN HONG KONG Suite 23A11, 23AthFloorTower 2, The GatewayHarbour City, KowloonHong Kong 223A23A11 PRINCIPAL BANKERS 18 China Construction Bank (Asia) Corporation LimitedCCB Centre18 Wang Chiu RoadKowloon BayHong Kong 95 China Construction Bank CorporationSuzhou Hi-Tech Industrial Development Zonesub-branchNo. 95 Shishan RoadSuzhou New District, Suzhou CityJiangsu ProvincePeople’s Republic of China AUDITOR 22 PricewaterhouseCoopersCertified Public Accountants andRegistered Public Interest Entity Auditor22/F, Prince’s BuildingCentralHong Kong Corporate Information PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICEIN THE CAYMAN ISLANDS Harneys Fiduciary (Cayman) Limited4th Floor, Harbour Place103 South Church Street, P.O. Box 10240Grand Cayman KY1-1002Cayman Islands Harneys Fiduciary (Cayman) Limited4th Floor, Harbour Place103 South Church Street, P.O. Box 10240Grand Cayman KY1-1002Cayman Islands HONG KONG BRANCH SHARE REGISTRAR AND TRANSFEROFFICE 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong COMPLIANCE ADVISER 3212101-2105 Fosun International Capital Limited2101-2105, 21/F, Champion Tower3 Garden Road, CentralHong Kong COMPANY WEBSITE https://cloudbreakpharma.com/ https://cloudbreakpharma.com/ Condensed Consolidated Interim Statement of Comprehensive Income For the six months ended 30 June 20252025630 Condensed Consolidated Interim Statement of Financial Position At 30 June 20252025630 Condensed Consolidated Interim Statement of Changes in Equity For the six months ended 30 June 20252025630 Condensed Consolidated Interim Statement of Changes in Equity For the six months ended 30 June 20252025630 Condensed Consolidated Interim Statement of Cash Flows For the six months ended 30 June 20252025630 Notes to the Condensed Consolidated Interim Financial Information For the six months ended 30 June 20252025630 1. 1.GENERAL INFORMATION 2 0 2 01 12 04th Floor, Harbour Place,103 South Church Street, P.O. Box10240, Grand Cayman KY1-1002,Cayman Islands891232308223A23A112025826 The Company was incorporated in the Cayman Islands on 20November 2020. The address of the Company’s registered office is4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240,Grand Cayman KY1-1002, Cayman Islands and the Company’sprincipal place of business in Hong Kong changed from Unit 2308, 23/F, Lippo Centre Tower 1, 89 Queensway, Hong Kong to Suite 23A11,23AthFloor, Tower 2, the Gateway, Harbour City, Kowloon, Hong Kongwith effect from 26 August 2025. Pursuant to the reorganisation of the Group in connection with thepreparation for the Listing, the Company became the investmentholding company of the Group on 13 January 2021 (the “GroupReorganisation”). Details of the Group Reorganisation wereset out in the paragraph headed “Our Company” of the sectionheaded “History, Reorganisation and Corporate Structure” in theProspectus. 2021113 The Company is an investment holding company and its subsidiariesare principally engaged in the research and development oftherapeutic biologics. The condensed consolidated interim financial information is presentedin US$, unless otherwise stat